Part IV · Molecular biology and therapeutic vulnerabilities · Chapter 16

Cell cycle regulation

The drug blocks one kinase. The cell has more than one way into S phase.

1 · The cyclin D, CDK4/6, and Rb axis

Mitogenic signalling converges on one transcriptional decision. Cyclin D accumulates in response to growth factor and hormone input, then binds CDK4 or CDK6. The resulting complex phosphorylates retinoblastoma protein. Hypophosphorylated Rb holds E2F transcription factors inactive until that phosphorylation releases them. S-phase genes are then transcribed.

Cyclin E is one of those genes, with its partner CDK2 phosphorylating Rb further and reinforcing the loop that produced it. Past a point the cell no longer needs the mitogen that started the process. That point is the restriction point, and CDK4/6 inhibitors work by holding the cell behind it.

Two families of inhibitor act on the complex, and they do not behave the same way. INK4 proteins, of which p16 is the one that matters here, bind CDK4 and CDK6 directly. The CIP and KIP proteins p21 and p27 behave differently depending on which complex they meet. They assist assembly of cyclin D with CDK4 and CDK6. They inhibit cyclin E with CDK2. Sequestering p21 and p27 into cyclin D complexes therefore relieves CDK2, which is a route into S phase needing no additional cyclin E.

The axis is a luminal dependency because oestrogen drives cyclin D1 transcription. Across 47 human breast cancer and immortalised cell lines, luminal ER-positive lines were the most sensitive to palbociclib and non-luminal basal lines the most resistant. Sensitive lines carried higher Rb and cyclin D1 and lower p16¹.

Rb status in practice is an immunohistochemistry call about whether the protein is present, which is not the same claim as whether it works. A cell carrying abundant Rb held constitutively phosphorylated is functionally Rb-null, and no routine assay reports that state.

2 · Rb loss, cyclin E amplification, and CDK6 upregulation

Three escape routes are established, and they are best ordered by how far downstream of the drug they act.

RB1 loss removes the node entirely, because a cell without functional Rb does not need CDK4 or CDK6 to release E2F. The cleanest clinical demonstration is the PALOMA-3 circulating tumour DNA analysis, set out in CDK4/6 inhibition and the evolution of cell cycle escape and not repeated here. Two things carry forward from it. RB1 alterations emerged only in the arm that received the inhibitor, and they did so in fewer than one patient in twenty. RB1 loss is a real mechanism but not the common one, and most progression on CDK4/6 inhibition has no RB1 alteration to account for it.

Acquired RB1 loss is also frequently polyclonal. Among three patients with RB1 mutations detected in circulating tumour DNA after palbociclib or ribociclib, one carried three distinct RB1 alterations at once². That is convergent evolution inside a single patient, and it is the pattern described in Convergent and divergent evolution and what each implies for sequencing.

CCNE1 amplification takes a different route. It restores S-phase entry through CDK2 rather than removing Rb. In PALOMA-3, tumour tissue was analysed from 302 randomised patients, 194 in the palbociclib arm and 108 in the placebo arm. Median progression-free survival in the palbociclib arm was 7.6 months where cyclin E1 messenger RNA was high, against 14.1 months where it was low. The corresponding placebo-arm figures were 4.0 and 4.8 months³. The separation is therefore about the drug rather than about prognosis alone.

The same analysis found no significant interaction between treatment effect and expression of CDK4, CDK6, cyclin D1 or RB1³. The genes a mechanistic account would nominate first did not predict. The one that did sits downstream of all of them.

CDK6 upregulation is the third route. It raises the amount of target rather than bypassing it. In a genomic analysis of 348 ER-positive breast cancers treated with CDK4/6 inhibitors, loss-of-function mutations in FAT1 were linked to resistance and produced marked elevation of CDK6⁴. The mechanism runs through Hippo signalling and is developed in Hippo signaling and FAT1 loss.

3 · Non-canonical routes to cell cycle escape

The routes above are selected over months of exposure. Escape also begins within days of the first dose, and the early form requires no genetic change at all.

ER-positive breast cancer cells evade cytostasis in part through non-canonical cyclin D1 with CDK2 complexes that carry them into S phase⁵. Co-treatment with endocrine therapy or with a PI3K inhibitor prevented that adaptation by lowering cyclin D1 and the other G1-S cyclins. This is the mechanistic reason CDK4/6 inhibitors are not given alone.

Upstream input matters as much as the node itself. Hyperactivation of EGFR and HER2 drives resistance to endocrine therapy and to CDK4/6 inhibition together⁶, while HER2 signalling destabilises p27 and so relieves CDK2⁷. Each of these reaches S phase without touching CDK4 or CDK6.

One distinction is worth holding throughout. Some escapes remove the requirement for CDK4 and CDK6, while others restore activity downstream of them. Only the first is genuinely independent of the drug class. The second can in principle be blocked again at the node it works through, which is the whole argument for CDK2 inhibition in CDK2, CDK7, and the next nodes.

The variants themselves have a source. APOBEC3 mutagenesis generates the hotspot alterations that define this escape set, RB1 loss among them⁸. Mutational process and selection are separate contributions, and an account that names only selection has described half the problem.

4 · Rb as a transcriptional coactivator under CDK4/6 inhibition

Activating a tumour suppressor sounds like an unambiguous good. In this pathway it is not.

CDK4/6 inhibition redistributes hypophosphorylated Rb onto promoters and enhancers. At cell cycle gene promoters Rb does what the textbook says and represses transcription. At other sites it does the opposite. It integrates into oestrogen receptor rich transcriptional hubs and promotes expression of oestrogen-responsive genes, mediated in part by an interaction with KDM5A⁹.

The consequence is not incidental, because components of that Rb-driven oestrogen programme are pro-proliferative. One drug therefore produces two opposing outputs from the same protein: arrest through E2F repression at cell cycle promoters, and a growth signal through coactivation at oestrogen-responsive loci.

This reframes what the endocrine partner is doing. In endocrine-sensitive disease, anti-oestrogen therapy neutralises the second output. That is a mechanistic account of the synergy rather than a restatement of it. In endocrine-resistant settings, including ESR1-mutant disease, the programme persists and limits what CDK4/6 inhibition can achieve⁹. The biology of ESR1 mutation is in Estrogen receptor signaling and endocrine resistance. Its clinical handling is in Metastatic hormone receptor-positive, HER2-negative disease.

5 · CDK2, CDK7, and the next nodes

CDK2 is where most escape routes converge. Cyclin E amplification acts through it, as does the non-canonical cyclin D1 complex responsible for early adaptation. Loss of p27 restraint acts through it as well. Cells that had acquired resistance through CCNE1 amplification were resensitised by targeting CDK2⁵.

The obstacle is selectivity. The active sites of CDK1 and CDK2 are closely similar, so an inhibitor that stops CDK2 in a tumour tends to stop CDK1 in normal proliferating tissue. That is a medicinal chemistry problem rather than a biological one. It is also why a node identified as a resistance mechanism years ago still has no registered agent against it.

CDK7 occupies a different position, serving as the CDK-activating kinase for several cell cycle CDKs while also forming part of the transcriptional machinery through phosphorylation of RNA polymerase II. Inhibiting it therefore strikes proliferation and transcription together. That dual action is at once the attraction of the target and its tolerability problem.

A phase I study of the oral CDK7 inhibitor samuraciclib gives the first clinical read. The maximum tolerated dose was 360 mg once daily. In the fulvestrant combination cohort, in HR-positive HER2-negative disease after a CDK4/6 inhibitor, three patients had a partial response. The clinical benefit rate at 24 weeks was 36.0%, which was 9 of 25 patients. Among patients with no detectable TP53 mutation it was 47.4%, or 9 of 19¹⁰.

Those figures carry the usual phase I limits. There was no control arm, and the TP53 subgroup was not a powered comparison. A clinical benefit rate at 24 weeks is not a progression-free survival estimate, and the two should not be read against each other.

A third direction narrows rather than extends. Inhibitors selective for CDK4 over CDK6 are in development on the argument that much of the haematological toxicity of the current class is a CDK6 effect in marrow progenitors. That is a dose-intensity argument. It does not address any of the escape routes in Rb loss, cyclin E amplification, and CDK6 upregulation.

6 · Senescence, mitotic slippage, and incomplete arrest

CDK4/6 inhibition arrests cells without killing them, and that single fact explains most of what the class does and most of what it does not.

The arrest is not a single state. Quiescence reverses when the drug is withdrawn, while senescence is a more stable exit accompanied by a secretory phenotype that acts on neighbouring cells. No assay in routine clinical tissue separates the two. The distinction matters because they predict different things about treatment holidays and about rechallenge, which is the argument developed in Genetic evolution and reversible cell state change as different problems.

The arrested cell is not inert. In mouse models and in serial biopsies from a clinical trial, CDK4/6 inhibition raised tumour cell expression of endogenous retroviral elements and intracellular double-stranded RNA. Type III interferon production and antigen presentation increased. Regulatory T-cell proliferation fell. Both arms of that response tracked reduced activity of DNA methyltransferase 1, an E2F target¹¹. The immune consequences are taken up in Breast cancer immunology.

Incomplete arrest is the practical problem. A drug that stops most cells leaves the remainder cycling under selection. That residual proliferating fraction is the substrate for every mechanism in Rb loss, cyclin E amplification, and CDK6 upregulation. Depth and continuity of target inhibition therefore matter more here than they would for a cytotoxic agent.

Mitotic slippage belongs to a different drug class and sits here for contrast. A cell held at the spindle assembly checkpoint can leave mitosis without dividing once checkpoint signalling decays. The product is a tetraploid cell carrying doubled and often damaged chromosomes. That is an entrance to the genomic instability described in DNA repair, replication stress, and genomic instability. It follows from failure to complete mitosis rather than from failure to arrest before S phase.

The escape routes in this chapter offer the next line of therapy very different things. RB1 loss is uncommon and currently unactionable. CCNE1 amplification and cyclin D1 with CDK2 adaptation point at CDK2. FAT1 loss and Hippo alteration point at CDK6 dosage and at PI3K, AKT, mTOR, and related networks. Rb-driven oestrogen transcription points back at the endocrine partner. What is done with each of these in metastatic disease is taken up in Metastatic hormone receptor-positive, HER2-negative disease.

References

1. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009 11:R77. PMID 19874578
2. Condorelli R, Spring L, O'Shaughnessy J, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol 2018 29:640-645. PMID 29236940
3. Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol 2019 37:1169-1178. PMID 30807234
4. Li Z, Razavi P, Li Q, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. Cancer Cell 2018 34:893-905. PMID 30537512
5. Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 2016 76:2301-2313. PMID 27020857
6. Belli S, et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. Cancer Lett 2024
7. Yang HY, et al. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000. PMID 10859299
8. Gupta A, Gazzo A, Selenica P, et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Nat Genet 2025 57:1452-1462. doi:10.1038/s41588-025-02187-1
9. Watt AC, et al. Rb-driven transcription limits its tumour-suppressive effects in breast cancer. Nature 2026. PMID 42587147
10. Coombes RC, Howell S, Lord SR, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat Commun 2023 14:4444. PMID 37488191
11. Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 2017 548:471-475. PMID 28813415